4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 561.25
-13.75 (-2.39%)
Jan 22, 2026, 9:58 AM GMT
4basebio Market Cap
4basebio has a market cap or net worth of 89 million as of January 22, 2026. Its market cap has decreased by -44.40% in one year.
Market Cap
89.00M
Enterprise Value
78.32M
Revenue
1.78M
Ranking
n/a
PE Ratio
n/a
Stock Price
561.25
Market Cap Chart
Since February 17, 2021, 4basebio's market cap has increased from 41.57M to 89.00M, an increase of 114.08%. That is a compound annual growth rate of 16.70%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 21, 2026 | 89.00M | -6.50% |
| Dec 31, 2025 | 95.19M | -38.57% |
| Dec 31, 2024 | 154.94M | 84.96% |
| Dec 29, 2023 | 83.77M | -4.21% |
| Dec 30, 2022 | 87.45M | 15.45% |
| Dec 31, 2021 | 75.75M | 82.22% |
| Feb 17, 2021 | 41.57M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 215.42B |
| GSK plc | 72.86B |
| Haleon | 32.16B |
| Smith & Nephew | 10.28B |
| Convatec Group | 4.51B |
| Hikma Pharmaceuticals | 3.42B |
| HUTCHMED (China) | 2.00B |
| Genus | 1.90B |